Agile Therapeutics Announces Delisting from Nasdaq

Written by Customer Service on March 25, 2024. Posted in Public Companies.

PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000. Suspension of trading in the Company’s common stock on the Nasdaq exchange will be effective at the open of trading on March 26, 2024. Following the Nasdaq delisting, shares of the Company’s common stock will continue to trade publicly. Effective March 26, 2024, the...

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Written by Customer Service on March 25, 2024. Posted in Public Companies.

CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference being held virtually on April 8-9, 2024. The Company’s presentation will take place on Monday, April 8, 2024, at 3:45 p.m. ET. Additionally, members of Zevra’s management team will be available for one-on-one investor meetings with registered attendees throughout the conference. The live webcast will be available here. Following Zevra’s presentation, the archived presentation will be accessible under “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com. To register for the conference, contact your Needham Sales Representative. About...

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

– Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers – – Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML treated under Compassionate Use shown in data presented at ASH 2023 – – Jane Chung promoted to President and Chief Operating Officer in November 2023 – – As of year-end 2023, Sutro had cash and investments of $333.7 million and shares of Vaxcyte common stock valued at $41.9 million, which together provide a projected cash runway into the second half of 2025 – SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Written by Customer Service on March 25, 2024. Posted in Public Companies.

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation. “We are pleased with the strong pace of enrollment in our Phase 2 BESTOW trial and believe it speaks to the underlying demand for a new immunosuppressive regimen for the tens of thousands of patients each year who undergo kidney transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer. The Risk of Organ Failure in Transplantation In transplantation procedures, organ rejection is a major cause of graft failure, which can be a life-threatening condition. Rejection occurs due to allorecognition,...

AppTech Payments Corp. Announces Proposed Underwritten Public Offering of Common Stock

Written by Customer Service on March 25, 2024. Posted in Public Companies.

CARLSBAD, Calif., March 25, 2024 (GLOBE NEWSWIRE) — AppTech Payments Corp. (Nasdaq: APCX) (“AppTech” or the “Company”), a pioneering Fintech company powering frictionless commerce, today announced that it intends to offer to sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. All of the shares of common stock and pre-funded warrants are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. EF Hutton LLC is acting as the sole book-running manager for the offering. AppTech intends to use the net proceeds from the offering for integration of existing business, working capital and general corporate purposes. The...

INNOVATE Corp. Announces Extension of Rights Offering Subscription Period

Written by Customer Service on March 25, 2024. Posted in Public Companies.

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m. Eastern Time on April 9, 2024, in order to allow stockholders and noteholders who are entitled to participate in the rights offering (holders of record of the Company’s common stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and 2026 Convertible Notes as of 5:00 p.m. Eastern Time on March 6, 2024) additional time to participate. The rights offering is being made pursuant to INNOVATE’s effective shelf registration statement on Form S-3, filed with the SEC on September 29, 2023 and declared effective on October 6, 2023, and a prospectus supplement containing the detailed...

Goodness Growth Holdings Reschedules Fourth Quarter and Full Year 2023 Results Call to April 1, 2024

Written by Customer Service on March 25, 2024. Posted in Public Companies.

MINNEAPOLIS, March 25, 2024 (GLOBE NEWSWIRE) — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that, due to scheduling conflicts, it has rescheduled its fourth quarter and full year results conference call for the year ended December 31, 2023 to Monday, April 1, 2024 after the market closes. Goodness Growth management will host a conference call with the investment community that day, Monday, April 1, 2024 at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number...

Enstar Subsidiary Assigned ‘A’ Financial Strength Rating by S&P Global

Written by Customer Service on March 25, 2024. Posted in Public Companies.

HAMILTON, Bermuda, March 25, 2024 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) announced today that the ratings agency S&P Global Ratings (“S&P”) has assigned an Insurer Financial Strength Rating of ‘A’ with stable outlook to its Bermuda-based, wholly owned subsidiary, Cavello Bay Reinsurance Limited (“Cavello Bay”). Cavello Bay is Enstar’s primary non-life run-off consolidator, and a Class 3B reinsurer. On issuing its rating, S&P highlighted Enstar’s competitive position as a “leader in the global non-life run-off market”, noting that it considers Enstar’s claims management capabilities to be “excellent”, as well as its expectation that Enstar will “continue executing large legacy transactions.” Matthew Kirk, Enstar’s Chief Financial Officer, said: “The S&P Insurer Financial Strength Rating is further...

MRC Global Announces First Quarter 2024 Earnings Release, Conference Call and Webcast Schedule

Written by Customer Service on March 25, 2024. Posted in Public Companies.

HOUSTON, March 25, 2024 (GLOBE NEWSWIRE) — MRC Global Inc. (NYSE: MRC) will release its first quarter 2024 results on May 8, 2024, after the market closes. In conjunction with the release, the company will host a conference call and webcast: What: MRC Global First Quarter 2024 Earnings Conference Call and Webcast When: Thursday, May 9, 2024, at 10:00 a.m. Eastern / 9:00 a.m. Central How: Via phone – Dial 201-689-8261 and ask for the MRC Global call prior to the start time, or Via webcast – Visit our website http://www.mrcglobal.com in the investor relations section A replay of the call will be available through May 23, 2024, by dialing 201-612-7415 using passcode 13745025#. An archive of the webcast will be available shortly after the call at www.mrcglobal.com for 90 days. About MRC Global Inc. Headquartered...

Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Schedules First Quarter 2024 Conference Call for May 1, 2024

Written by Customer Service on March 25, 2024. Posted in Public Companies.

MIDLAND, Texas, March 25, 2024 (GLOBE NEWSWIRE) — Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”), a subsidiary of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release first quarter 2024 financial results on April 30, 2024 after the market closes. In connection with the earnings release, Viper will host a conference call and webcast for investors and analysts to discuss its results for the first quarter of 2024 on Wednesday, May 1, 2024 at 10:00 a.m. CT. Access to the live webcast, and replay which will be available following the call, may be found here. The live webcast of the earnings conference call will also be available via Viper’s website at www.viperenergy.com under the “Investor Relations” section of the site. About Viper Energy, Inc. Viper is an oil and gas company formed by Diamondback...

Day: March 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice